Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?
Paclitaxel is a successful anti-cancer drug that kills cancer cells in two-dimensional culture through perturbation of mitosis, but whether it causes tumour regression by anti-mitotic actions is controversial. Drug candidates that specifically target mitosis, including inhibitors of kinesin-5, AurkA...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
The Royal Society
2017-01-01
|
Series: | Open Biology |
Subjects: | |
Online Access: | https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.170182 |